There is a strong demand for Covaxin manufactured by Hyderabad based pharma company Bharat Biotech International Ltd (BBIL) from many countries and the firm reported that its fully committed to ensuring supplies promptly and efficiently.
It is known that BBIL on Friday announced that it has signed a pact with Brazil for the supply of 20 million doses of Covaxin vaccine to battle COVID-19. BBIL signed an agreement for the delivery of Covaxin during Q2 and Q3 2021 lately. The spokesperson of the company stated that it is delighted to tie up with Brazil in its attempt to curb COVID-19 and aid its vaccination program against the virus.
In this process, Hyderabad-based Indian Council of scientific and industrial research (CSIR)- Indian Institute of Chemical Technology (IICT) played a crucial role in optimising the synthesis of agonist molecules to be utilised for developing Covaxin. It was contacted by Bharat Biotech to generate the synthetic route for the agonist molecule with indigenous chemicals at an economical price and with highest purity. This agonist molecule has favoured in expanding the production of the adjuvant, IICT said.
The process technology developed by CSIR-IICT for the agonist molecule is learnt to have a significant role in the production of adjuvant for Covaxin,” said Shekhar Mande, DG, CSIR and Secretary, DSIR.